Charlie Schmidt. Show Affiliations »
Abstract
Entities: Chemical Disease
Mesh: See more » Antibodies, Monoclonal/adverse effectsAntibodies, Monoclonal/immunologyAntibodies, Monoclonal/therapeutic useAntibodies, Monoclonal, HumanizedDrug ApprovalHumansInterleukin-12/antagonists & inhibitorsInterleukin-12/immunologyInterleukin-23/antagonists & inhibitorsInterleukin-23/immunologyPsoriasis/drug therapyPsoriasis/immunologyUnited StatesUnited States Food and Drug AdministrationUstekinumab
Substances: See more » Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedInterleukin-23Interleukin-12Ustekinumab
Year: 2008 PMID: 19060851 DOI: 10.1038/nbt1208-1317a
Source DB: PubMed Journal: Nat Biotechnol ISSN: 1087-0156 Impact factor: 54.908